Last reviewed 2026-04-22 · How we verify

Novolin 70/30

Novolin 70/30 is a fixed-ratio insulin combination that replaces or supplements the body's natural insulin to regulate blood glucose levels.

Novolin 70/30 is a fixed-ratio insulin combination that replaces or supplements the body's natural insulin to regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Mechanism of action

Novolin 70/30 contains 70% NPH insulin (intermediate-acting) and 30% regular insulin (short-acting). The regular insulin component acts quickly to lower postprandial glucose, while the NPH component provides sustained glucose control throughout the day and overnight. Together, they mimic the body's natural biphasic insulin secretion pattern.

Approved indications

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus

Common side effects

• Hypoglycemia
• Injection site reactions
• Lipodystrophy
• Weight gain

Key clinical trials

• Glycemic Targets During CPB in Elderly Diabetes (NA)
• MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes (PHASE1)
• Effect of Insulin Lowering on Lipogenesis (PHASE1)
• ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells (PHASE1, PHASE2)
• iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
• Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
• The Effect of Locally Dilvered Ciprofloxacine Loaded Injectable Platelet-rich Fibrin as an Adjunct to Non-surgical Periodontal Therapy on the Gingival Crevicular Level of Interleukin 6 (NA)
• Effect of a Dietary Intervention on Intracellular Lipid Levels, Insulin Sensitivity, and Glycemic Control in Type 2 Diabetes (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.